KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Interest & Investment Income: 2009-2024

Historic Interest & Investment Income for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $74.9 million.

  • Biomarin Pharmaceutical's Interest & Investment Income fell 1.10% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $74.9 million for FY2024, which is 28.36% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Interest & Investment Income of $74.9 million as of FY2024, which was up 28.36% from $58.3 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Interest & Investment Income ranged from a high of $74.9 million in FY2024 and a low of $10.5 million during FY2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $58.3 million (2023), whereas its average is $50.4 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 36.89% in 2021, then skyrocketed by 223.49% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Interest & Investment Income (Yearly) stood at $16.6 million in 2020, then tumbled by 36.89% to $10.5 million in 2021, then spiked by 72.05% to $18.0 million in 2022, then surged by 223.49% to $58.3 million in 2023, then grew by 28.36% to $74.9 million in 2024.